INM - InMed Pharmaceuticals announces $5M registered direct and private placement offerings

InMed Pharmaceuticals (NASDAQ:INM) -4% has entered into securities purchase agreements with a single healthcare-focused institutional investor for the issuance and sale of 4.08M common shares at a purchase price of $0.858 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed (INM) has also agreed to issue and sell to the investor 1,748,250 common shares (or pre-funded warrant in lieu thereto) at the same purchase price as in the registered direct offering. In addition, the Company has agreed to issue unregistered preferred investment options to purchase up to an aggregate of 5,827,506 common shares. The aggregate gross proceeds of both offerings are expected to be ~$5M. Net proceeds will be used to continue pipeline development, advance commercial activities and for general working capital purposes. Closing date is June 6, 2022. The unregistered investment options to be issued in the

For further details see:

InMed Pharmaceuticals announces $5M registered direct and private placement offerings